Royal Philips, a global leader in health technology, announced 510(k) clearance from the US Food and Drug Administration (FDA) to market its ElastQ Imaging capability, further expanding the functionalities of its EPIQ family of ultrasound systems.
ElastQ Imaging enables simultaneous imaging of tissue and assessment of its stiffness, which is essential for the diagnosis of various liver conditions. With ElastQ Imaging, clinicians have a comprehensive solution to assess and diagnose liver conditions without the pain or expense of a liver biopsy. Using shear wave elastography to focus sound waves to assess soft tissue stiffness, ElastQ Imaging is non-invasive, reproducible and easily executed. Philips is at the forefront of imaging technology innovation, and with this new capability is addressing a significant need of medical professionals in the clinical setting.
Liver disease, which includes hepatitis B and C, liver cancer and cirrhosis, is a growing global health issue due in part to rising obesity rates and an aging population. Non-alcoholic fatty liver disease affects approximately 20% of the global population. According to the World Health Organization (WHO), total deaths worldwide from cirrhosis and liver cancer rose by 50 million per year over the last two decades, and many cases continue to go undetected.
To determine the stage of liver disease and damage, a liver biopsy is typically performed by extracting a small piece of liver tissue for microscopic examination. Research suggests that instead of costly and painful biopsy procedures, ultrasound exams using shear wave elastography could become routine for assessing liver disease status and may reduce or avoid the need for conventional liver biopsies.
“Philips aims to provide the tools necessary for assessing and managing chronic conditions that so many people face, and liver disease is no exception,” said Vitor Rocha, Ultrasound Business Leader at Philips. “We know that liver disease is a growing health concern around the globe, and we are committed to pioneering innovations like ElastQ Imaging to create our ultimate ultrasound liver solution that offers exceptional clinical performance, further improving patient care.”
Philips ElastQ Imaging shear wave elastography offers: Larger field of view or Region of Interest (ROI) than competitors; Color-coded quantitative assessment of tissue stiffness; Real-time feedback and intelligent analysis; Quantitative measurements with multiple sample points.
In addition to ElastQ Imaging, Philips’ ultimate ultrasound liver solution is comprised of a suite of features that make it a powerful tool for clinicians, including: PureWave transducer technology, delivering superb image quality and increased penetration in technically difficult-to-image patients; Contrast enhanced ultrasound, providing confidence in liver lesion detection and characterization; Image fusion and navigation with anatomical intelligence, increasing the power of real-time ultrasound exams through multimodality fusion and interventional guidance.
Improving the exam experience for both patients and clinicians is a critical part of Philips’ mission to improve the quality of healthcare with patient-centric solutions. The ultimate ultrasound liver solution combines a routine ultrasound imaging exam of the liver anatomy with targeted tissue stiffness values, allowing clinicians to obtain a baseline assessment without the wait time associated with tissue biopsy. For patients, the non-invasive ultrasound exam is more comfortable than a traditional liver biopsy that requires the use of needles. The exam results from ultrasound are also available instantly, which can help reduce apprehension patients may feel in waiting for test results.
“There is a significant population at risk for liver disease that may not even know it,” said Richard G. Barr, MD, PhD, radiologist, Southwoods Imaging, in Youngstown, Ohio. “As a Radiologist, I see every day how important liver assessment is becoming, and I’m hopeful that this solution will help patients get the diagnosis, monitoring and treatment they need.”